BR112013007343A2 - métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica - Google Patents
métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópicaInfo
- Publication number
- BR112013007343A2 BR112013007343A2 BR112013007343A BR112013007343A BR112013007343A2 BR 112013007343 A2 BR112013007343 A2 BR 112013007343A2 BR 112013007343 A BR112013007343 A BR 112013007343A BR 112013007343 A BR112013007343 A BR 112013007343A BR 112013007343 A2 BR112013007343 A2 BR 112013007343A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating rosacea
- telangiectasia
- erythema
- methods
- topical composition
- Prior art date
Links
- 241001303601 Rosacea Species 0.000 title abstract 5
- 201000004700 rosacea Diseases 0.000 title abstract 5
- 206010015150 Erythema Diseases 0.000 title abstract 4
- 206010043189 Telangiectasia Diseases 0.000 title abstract 4
- 231100000321 erythema Toxicity 0.000 title abstract 4
- 208000009056 telangiectasis Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 title abstract 3
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 1
- 229960003679 brimonidine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960001528 oxymetazoline Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38726010P | 2010-09-28 | 2010-09-28 | |
| US13/232,134 US20120082625A1 (en) | 2010-09-28 | 2011-09-14 | Combination treatment for rosacea |
| PCT/US2011/053440 WO2012047645A2 (en) | 2010-09-28 | 2011-09-27 | Combination treatment for rosacea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013007343A2 true BR112013007343A2 (pt) | 2016-07-05 |
Family
ID=45890007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013007343A BR112013007343A2 (pt) | 2010-09-28 | 2011-09-27 | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20120082625A1 (https=) |
| EP (1) | EP2621497A4 (https=) |
| JP (1) | JP2013538853A (https=) |
| KR (1) | KR20140056130A (https=) |
| CN (1) | CN103354743A (https=) |
| AU (1) | AU2011312518A1 (https=) |
| BR (1) | BR112013007343A2 (https=) |
| CA (1) | CA2811783A1 (https=) |
| MX (1) | MX2013003638A (https=) |
| RU (1) | RU2013113184A (https=) |
| WO (1) | WO2012047645A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| JP6030067B2 (ja) * | 2010-12-03 | 2016-11-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的クリーム組成物および使用法 |
| BR112013020770A2 (pt) | 2011-02-15 | 2019-08-27 | Allergan, Inc. | composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea |
| CN104666239A (zh) * | 2013-11-27 | 2015-06-03 | 杭州赛利药物研究所有限公司 | 酒石酸溴莫尼定凝胶及其制备方法 |
| KR20170132725A (ko) * | 2015-02-24 | 2017-12-04 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 안구 건조 질환 및 다른 안과 질환을 치료하기 위한 방법 및 조성물 |
| US9989950B2 (en) | 2015-07-17 | 2018-06-05 | General Electric Company | Systems and methods for generating control logic |
| FR3041537B1 (fr) * | 2015-09-29 | 2018-11-30 | Galderma Research & Development | Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee. |
| WO2017161432A1 (pt) * | 2016-03-22 | 2017-09-28 | Doris Maria Hexsel | Uso de uma composição farmacêutica destinada ao tratamento do eritema cutâneo das poiquilodermias |
| EP3476393A4 (en) * | 2016-06-28 | 2019-07-17 | Doris Maria Hexsel | USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA |
| CA3039561A1 (en) * | 2016-10-07 | 2018-04-12 | Micreos Human Health B.V. | Vasoconstrictive and antibacterial combination treatment for rosacea |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| RU2766973C1 (ru) * | 2021-10-05 | 2022-03-16 | Татьяна Сергеевна Русина | Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| JP4955543B2 (ja) * | 2004-05-25 | 2012-06-20 | サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド | 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法 |
| JP5670196B2 (ja) * | 2007-11-16 | 2015-02-18 | バイセプト セラピューティクス、インク． | 紫斑を治療する組成物および方法 |
| FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
-
2011
- 2011-09-14 US US13/232,134 patent/US20120082625A1/en not_active Abandoned
- 2011-09-27 EP EP11831290.9A patent/EP2621497A4/en not_active Withdrawn
- 2011-09-27 BR BR112013007343A patent/BR112013007343A2/pt not_active IP Right Cessation
- 2011-09-27 CN CN2011800470779A patent/CN103354743A/zh active Pending
- 2011-09-27 RU RU2013113184/15A patent/RU2013113184A/ru not_active Application Discontinuation
- 2011-09-27 KR KR1020137010904A patent/KR20140056130A/ko not_active Ceased
- 2011-09-27 AU AU2011312518A patent/AU2011312518A1/en not_active Abandoned
- 2011-09-27 WO PCT/US2011/053440 patent/WO2012047645A2/en not_active Ceased
- 2011-09-27 JP JP2013531717A patent/JP2013538853A/ja active Pending
- 2011-09-27 MX MX2013003638A patent/MX2013003638A/es unknown
- 2011-09-27 CA CA2811783A patent/CA2811783A1/en not_active Abandoned
-
2013
- 2013-12-09 US US14/100,450 patent/US20140100232A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,519 patent/US20150313894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2621497A4 (en) | 2014-03-05 |
| JP2013538853A (ja) | 2013-10-17 |
| WO2012047645A2 (en) | 2012-04-12 |
| CA2811783A1 (en) | 2012-04-12 |
| MX2013003638A (es) | 2013-08-29 |
| CN103354743A (zh) | 2013-10-16 |
| US20120082625A1 (en) | 2012-04-05 |
| AU2011312518A1 (en) | 2013-04-18 |
| EP2621497A2 (en) | 2013-08-07 |
| US20150313894A1 (en) | 2015-11-05 |
| RU2013113184A (ru) | 2014-11-10 |
| US20140100232A1 (en) | 2014-04-10 |
| KR20140056130A (ko) | 2014-05-09 |
| WO2012047645A3 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
| BR112013022801A2 (pt) | combinações de terapia para malignidades hematológicas | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| BR112012021086A2 (pt) | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos | |
| BR112013005432A8 (pt) | tratamento de doenças | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| BR112015008459A2 (pt) | método veterinário de aliviar a aversão ao ruído | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| ATE543492T1 (de) | Behandlung von lungenkrebs | |
| BR112012020060A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero. | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| BR112013006651A2 (pt) | composição e cocristal de aprepitante l-prolina | |
| BR112012009388A2 (pt) | derivados de apogossipolone como agentes anticâncer | |
| UY33332A (es) | Compuestos de triazol como inhibidores de ksp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |